Clinical Trials

Searchable database of currently enrolling clinical trials

Can PARP Inhibitors Make It into the Metastatic Castration-Sensitive Prostate Cancer Disease State?

Evan Y. Yu
February 01, 2022

I’m continuing this series focused on metastatic castration-sensitive prostate cancer (mCSPC), as it is a disease state with many upcoming potential changes to standard of care.  A couple of months ago, I briefly summarized what is known about the PEACE-1 trial, and I highlighted ongoing chemohormonal therapy trials.1  Since then, there has been a press release that the ARAMIS trial with androgen deprivation therapy (ADT) plus docetaxel and darolutamide is superior in overall survival compared to ADT plus docetaxel.  We eagerly await the data to be presented at the upcoming 2022 ASCO Genitourinary Cancers Symposium.  Additionally, just last month, I summarized the trials that are ongoing using PD-1/PD-L1 antibody inhibition for patients with mCSPC.2  Although single agent PD-1/PD-L1 inhibitors have not shown definitive promise yet in metastatic castration-resistant prostate cancer (mCRPC) for unselected populations, hope remains that earlier use may offer benefit to our patients.

READ MORE PREVIOUS ARTICLES

Dr. Evan Yu, MD

Evan Yu, MD

Evan Yu, a medical oncologist, treats prostate, bladder, and testicular cancer, and is passionate about providing a personalized medical approach to a selection of novel therapies as well as understanding biologic mechanism of drug sensitivity and resistance.

Clinical Expertise

Medical Oncology, Translational Research, Novel molecular targeted agents, Biomarkers, Imaging (PET scans, MRI), Bone health.

  • Professor, Department of Medicine, Division of Oncology, University of Washington School of Medicine
  • Member, Clinical Research Division, Fred Hutchinson Cancer Research Center
  • Clinical Research Director, Genitourinary Oncology, Seattle Cancer Care Alliance
  • Medical Director, Clinical Research Service, Fred Hutchinson Cancer Research Consortium
Search Clinical Trials by Disease

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date. Please remember: Talk to your health care providers first before making decisions about your health care. Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

email news signup